Revvity Inc. (NYSE:RVTY) Receives $108.36 Consensus PT from Analysts

Shares of Revvity Inc. (NYSE:RVTY) have been assigned a consensus recommendation of “Hold” from the fifteen analysts that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $108.3636.

Several equities analysts recently issued reports on RVTY shares. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Evercore restated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Stifel Nicolaus cut their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday, May 6th. Sanford C. Bernstein began coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th.

Revvity Stock Performance

RVTY stock opened at $116.71 on Thursday. Revvity has a 1-year low of $81.22 and a 1-year high of $118.34. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The firm has a market cap of $13.02 billion, a PE ratio of 55.58, a P/E/G ratio of 2.13 and a beta of 1.07. The business’s 50-day moving average price is $109.62 and its two-hundred day moving average price is $100.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts forecast that Revvity will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Hedge Funds Weigh In On Revvity

A number of large investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC bought a new stake in shares of Revvity in the second quarter valued at about $961,017,000. BlackRock Inc. acquired a new stake in Revvity in the 2nd quarter valued at approximately $852,070,000. Primecap Management Co. CA bought a new stake in Revvity in the 2nd quarter valued at approximately $94,921,000. Norges Bank acquired a new position in Revvity during the 4th quarter worth approximately $80,382,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Revvity during the 2nd quarter worth approximately $78,766,000. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.